Terms: = Lung cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2
5126 results:
1. Targeting kras in pancreatic cancer.
Stickler S; Rath B; Hamilton G
Oncol Res; 2024; 32(5):799-805. PubMed ID: 38686056
[TBL] [Abstract] [Full Text] [Related]
2. Drugging the undruggable: Advances in targeting kras signaling in solid tumors.
Tripathi P; Kumari R; Pathak R
Int Rev Cell Mol Biol; 2024; 385():1-39. PubMed ID: 38663957
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.
Sun Y; Qin S; Wang S; Pang J; Ou Q; Liang W; Zhong H
J Pathol Clin Res; 2024 May; 10(3):e12375. PubMed ID: 38661052
[TBL] [Abstract] [Full Text] [Related]
4. Temporal trends and regional variability in BRAF and kras genetic testing in Denmark (2010-2022): Implications for precision medicine.
Frost MG; Jensen KJ; Jimenez-Solem E; Qvortrup C; Kuhlmann TP; Andersen JL; Høgdall E; Petersen TS
Genes Chromosomes Cancer; 2024 Apr; 63(4):e23236. PubMed ID: 38656617
[TBL] [Abstract] [Full Text] [Related]
5. Targeting kras in cancer.
Singhal A; Li BT; O'Reilly EM
Nat Med; 2024 Apr; 30(4):969-983. PubMed ID: 38637634
[TBL] [Abstract] [Full Text] [Related]
6. Targeting kras Diversity: Covalent Modulation of G12X and Beyond in cancer Therapy.
Kirschner T; Müller MP; Rauh D
J Med Chem; 2024 Apr; 67(8):6044-6051. PubMed ID: 38621359
[TBL] [Abstract] [Full Text] [Related]
7. Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker lung Adenocarcinoma Patients without EGFR or ALK Alterations.
Park SJ; Ju S; Goh SH; Yoon BH; Park JL; Kim JH; Lee S; Lee SJ; Kwon Y; Lee W; Park KC; Lee GK; Park SY; Kim S; Kim SY; Han JY; Lee C
Cancer Res; 2024 May; 84(9):1491-1503. PubMed ID: 38607364
[TBL] [Abstract] [Full Text] [Related]
8. Genetic Signature of Human Pancreatic cancer and Personalized Targeting.
Reshkin SJ; Cardone RA; Koltai T
Cells; 2024 Mar; 13(7):. PubMed ID: 38607041
[TBL] [Abstract] [Full Text] [Related]
9. Targeted therapeutic options in early and metastatic NSCLC-overview.
Gálffy G; Morócz É; Korompay R; Hécz R; Bujdosó R; Puskás R; Lovas T; Gáspár E; Yahya K; Király P; Lohinai Z
Pathol Oncol Res; 2024; 30():1611715. PubMed ID: 38605928
[TBL] [Abstract] [Full Text] [Related]
10. Precision nanomedicine to treat non-small cell lung cancer.
Dessai A; Nayak UY; Nayak Y
Life Sci; 2024 Jun; 346():122614. PubMed ID: 38604287
[TBL] [Abstract] [Full Text] [Related]
11. [Clinical characteristics and prognosis analysis of pulmonary sarcomatoid carcinoma].
Feng XY; Chen MJ; Xu Y; Zhong W; Liu XY; Gao XX; Zhao J; Wang MZ
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Apr; 47(4):319-324. PubMed ID: 38599806
[No Abstract] [Full Text] [Related]
12. Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With
Luo J; Florez N; Donnelly A; Lou Y; Lu K; Ma PC; Spira AI; Ryan D; Husain H
JCO Precis Oncol; 2024 Apr; 8():e2300644. PubMed ID: 38579193
[TBL] [Abstract] [Full Text] [Related]
13. lung cancer Clinical Trials in Latin America in the Era of Cooperative Groups: A 20-Year Analysis.
Knapp T; Nygaard J; Cassinat J; Galvez F; Gopalan PK
JCO Glob Oncol; 2024 Apr; 10():e2300379. PubMed ID: 38574300
[TBL] [Abstract] [Full Text] [Related]
14. Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients with kras mutations: A network meta-analysis.
Zhang L; Chen W; Wei H; Yu J
Clin Respir J; 2024 Apr; 18(4):e13745. PubMed ID: 38566277
[TBL] [Abstract] [Full Text] [Related]
15. Discovering single cannabidiol or synergistic antitumor effects of cannabidiol and cytokine-induced killer cells on non-small cell lung cancer cells.
Li Y; Sharma A; Hoffmann MJ; Skowasch D; Essler M; Weiher H; Schmidt-Wolf IGH
Front Immunol; 2024; 15():1268652. PubMed ID: 38558822
[TBL] [Abstract] [Full Text] [Related]
16. [Colorectal adenocarcinoma with enteroblastic differentiation: a clinicopathological analysis of eight cases].
Wang Q; Zhang Y; Tan C; Ni SJ; Huang D; Chang B; Sheng WQ; Wang L
Zhonghua Bing Li Xue Za Zhi; 2024 Apr; 53(4):370-376. PubMed ID: 38556821
[No Abstract] [Full Text] [Related]
17. Targeting
Ros J; Vaghi C; Baraibar I; Saoudi González N; Rodríguez-Castells M; García A; Alcaraz A; Salva F; Tabernero J; Elez E
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542278
[TBL] [Abstract] [Full Text] [Related]
18. Red blood cells function as reservoirs of tumor DNA.
Thompson JC; Li S; Jose JS; Predina J; Gupta A; Eruslanov E; Singhal S; Albelda SM; Mangalmurti NS
Am J Physiol Lung Cell Mol Physiol; 2024 May; 326(5):L646-L650. PubMed ID: 38529551
[TBL] [Abstract] [Full Text] [Related]
19. Prediction performance comparison of biomarkers for response to immune checkpoint inhibitors in advanced non-small cell lung cancer.
Zhao J; Zhuang W; Sun B; Bai H; Wang Z; Zhong J; Wan R; Liu L; Duan J; Wang J
Thorac Cancer; 2024 May; 15(13):1050-1059. PubMed ID: 38528429
[TBL] [Abstract] [Full Text] [Related]
20. If it's a target, it's a pan-cancer target: Tissue is not the issue.
Adashek JJ; Kato S; Sicklick JK; Lippman SM; Kurzrock R
Cancer Treat Rev; 2024 Apr; 125():102721. PubMed ID: 38522181
[TBL] [Abstract] [Full Text] [Related]
[Next]
